Source comparison
Pulsatile GH Secretion vs Continuous Elevation
Growth hormone is not secreted continuously. It's released in discrete pulses, primarily during slow-wave sleep and in response to exercise, hypoglycemia, or amino acid intake. These pulses are regulated by the balance between GHRH (which stimulates secretion)
This comparison does not assign a generated winner or score.
- Growth hormone is not secreted continuously. It's released in discrete pulses, primarily during slow-wave sleep and in response to exercise, hypoglycemia, or amino acid intake. These pulses are regulated by the balance between GHRH (which stimulates secretion) and somatostatin (which inhibits it). Endogenous GH pulse amplitude ranges from 5–20 ng/mL peak concentration, with 6–10 pulses per 24-hour period in healthy adults. The pulsatile pattern matters because GH receptor signaling in peripheral tissues (liver, muscle, adipose) is not linear with concentration. Receptor occupancy and downstream JAK-STAT pathway activation are maximized during high-amplitude pulses, not sustained low-level exposure.
- CJC-1295 amplifies pulse amplitude without increasing pulse frequency or creating continuous GH elevation. This is the critical distinction from exogenous GH administration, which suppresses endogenous secretion via negative feedback on the hypothalamus and pituitary. When you inject recombinant GH, plasma levels rise to supraphysiological concentrations (50–100 ng/mL or higher), but this also triggers compensatory somatostatin release, which inhibits the pituitary's ability to respond to GHRH. Over time, this causes somatotroph atrophy. The cells stop producing GH because they're receiving constant negative feedback. CJC-1295 works with the existing pulse architecture: it increases the height of each pulse but leaves the timing intact, which means somatotroph cells remain sensitive to endogenous GHRH signals.
- Clinical data from a Phase 2 trial published in Clinical Endocrinology showed that subjects receiving CJC-1295 maintained pulse frequency of 8–12 events per 24 hours, identical to baseline, but mean pulse amplitude increased by 3–6 fold. IGF-1 levels. The downstream mediator of GH effects. Rose by 1.5–2.5 times baseline and remained elevated for 6–11 days post-injection. This pattern is fundamentally different from continuous GH infusion, which produces higher peak IGF-1 but also triggers compensatory mechanisms (increased IGF-binding protein production, reduced GH receptor density) that attenuate the response over time. Pulsatile signaling avoids receptor desensitization because cells experience periods of low GH exposure between pulses, during which receptor expression recovers.